Doravirine combination pill looks good for initial HIV treatment
New integrase inhibitor bictegravir works well for first-line HIV treatment
Long-acting cabotegravir + rilpivirine injection shows good results at 96 weeks
Bone density improves in people who switch from tenofovir DF to tenofovir alafenamide
Research helps explain how vedolizumab antibody therapy leads to sustained viral remission
Several new candidates in HIV drug pipeline discussed at conference
Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good
New HIV capsid inhibitors show high potency and prolonged activity in early studies
Monoclonal antibodies show promise for HIV-positive people with limited treatment options
